» Articles » PMID: 19520974

High Levels of Myeloid-related Protein 14 in Human Atherosclerotic Plaques Correlate with the Characteristics of Rupture-prone Lesions

Overview
Date 2009 Jun 13
PMID 19520974
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Atherosclerotic plaque rupture can lead to severe complications such as myocardial infarction and stroke. Myeloid related protein (Mrp)-14, Mrp-8, and Mrp-8/14 complex are inflammatory markers associated with myocardial infarction. It is, however, unknown whether Mrps are associated with a rupture-prone plaque phenotype. In this study, we determined the association between Mrp-14, -8, -8/14 plaque levels and plaque characteristics.

Methods And Results: In 186 human carotid plaques, levels of Mrp-14, -8, and -8/14 were quantified using ELISA. High levels of Mrp-14 were found in lesions with a large lipid core, high macrophage staining, and low smooth muscle cell and collagen amount. Plaques with high levels of Mrp-14 contained high interleukin (IL)-6, IL-8, matrix metalloprotease (MMP)-8, MMP-9, and low MMP-2 concentrations. Mrp-8 and Mrp-8/14 showed a similar trend. Within plaques, a subset of nonfoam macrophages expressed Mrp-8 and Mrp-14 and the percentage of Mrp-positive macrophages was higher in rupture-prone lesions compared to stable ones. In vitro, this subset of macrophages does not acquire a foamy phenotype when fed oxLDL.

Conclusions: Mrp-14 is strongly associated with the histopathologic features and the inflammatory status of rupture-prone atherosclerotic lesions, identifying Mrp-14 as a local marker for these plaques.

Citing Articles

Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasis.

Armyra K, Ektesabi A, Tsoporis J, Izhar S, Triantafyllis A, Leong-Poi H Pharmacol Rep. 2025; .

PMID: 40085417 DOI: 10.1007/s43440-025-00710-z.


S100a8/A9 proteins: critical regulators of inflammation in cardiovascular diseases.

Sun Y, Xu H, Gao W, Deng J, Song X, Li J Front Cardiovasc Med. 2024; 11:1394137.

PMID: 39175627 PMC: 11338807. DOI: 10.3389/fcvm.2024.1394137.


Circulating Levels of Calprotectin as a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Reshadmanesh T, Behnoush A, Farajollahi M, Khalaji A, Ghondaghsaz E, Ahangar H Clin Cardiol. 2024; 47(7):e24315.

PMID: 38961752 PMC: 11222710. DOI: 10.1002/clc.24315.


Advances in the study of S100A9 in cardiovascular diseases.

Chen F, He Z, Wang C, Si J, Chen Z, Guo Y Cell Prolif. 2024; 57(8):e13636.

PMID: 38504474 PMC: 11294427. DOI: 10.1111/cpr.13636.


Plasma Calprotectin Levels Associate With New-Onset Hypertension in the General Population: A Prospective Cohort Study.

Bourgonje A, Bourgonje M, la Bastide-van Gemert S, Nilsen T, Hidden C, Gansevoort R J Am Heart Assoc. 2023; 13(1):e031458.

PMID: 38156449 PMC: 10863804. DOI: 10.1161/JAHA.123.031458.